On November 6, 2009
Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
Is this a rare case of Teva Pharmaceutical being forced to swallow its own bitter medicine? The world’s largest generic manufacturer, with a core value founded on its unflinching willingness to challenge the patented protection of branded products owned by other drugmakers, is suing generic rival Mylan. Teva alleges patent infringement of its flagship multiple sclerosis drug Copaxone, and reiterates that intellectual property rights covering chemical (s) composition and methods to use it are protected through May 2014.
0 Comments